Larvol Delta - Cognition-Therapeutics-and-ACTC-Receive-FDA-Clearance-for-Phase-2-START-Study-of-Oral-CT1812-in-Early-Alzheimers-Disease

Elayta (CT1812) - Cognition Therap

https://www.globenewswire.com/news-release/2023/02/22/2613183/0/en/Cognition-Therapeutics-and-ACTC-Receive-FDA-Clearance-for-Phase-2-START-Study-of-Oral-CT1812-in-Early-Alzheimer-s-Disease.html

Feb 22, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next